- The shares of Co-Diagnostics ( NASDAQ: CODX ) reached over a three-month high after the molecular diagnostics company announced the shipment of testing reagents for the monkeypox virus to one of its international distributors.
- Co-Diagnostics ( CODX ) said that the products it shipped were designed and developed on an expedited basis to suit the demands of the distributor’s region.
- The recent monkeypox outbreak has benefitted the companies focused on vaccines and therapeutics for the rare viral disease as the global case count exceeded more than 6,000 as of July 07.
- This month, the World Health Organization (WHO) plans to convene an advisory meeting to decide whether the outbreak amounts to a global health emergency.
- “We are grateful to our dedicated design and manufacturing teams, whose efforts have allowed us to react so quickly to meet the needs of an important distributor customer,” Chief Executive Dwight Egan noted.
- In May, Co-Diagnostics ( CODX ) announced the completion of the principal design work for a PCR-based monkeypox test.
For further details see:
Co-Diagnostics spikes on shipments of monkeypox test